Advancing the world of health™
- 关于碧迪医疗
- 版块
碧迪医疗是全球最大的跨国医疗技术公司之一，致力于改善医学发现方法、医疗诊断效果和护理质量，以引领世界健康。公司致力于研发创新技术、服务和解决方案，为一线医务工作者提供支持，帮助改善患者的临床治疗，同时帮助医护人员改进临床流程。碧迪医疗及其75,000名全球员工秉承高昂的热情和信念，为临床医护人员提供安全、高效的护理给药流程，协助实验室科学家们更有效地诊断疾病，并提升科研人员研发新一代诊断技术及治疗方法的能力。碧迪医疗在几乎所有国家和地区均设有分支机构，与全球范围内的组织机构积极合作，携手应对最具挑战的全球健康问题。通过与客户的密切合作，碧迪医疗可以帮助提高疗效，降低成本，提高效率，改善安全性，并扩大医疗服务的范围。
Made for today, tomorrow and for what’s needed next.
碧迪医疗致力于建立强烈的道德与合规文化氛围。对与我们价值观不符或违反碧迪医疗《行为准则》或适用法律法规的行为，概不容忍。碧迪医疗所有员工都有责任加强道德与合规文化建设，维持公司崇尚质量和诚信的声誉。我们鼓励并期望碧迪医疗每一位员工发声，提出疑问、提出关切、寻求指导以及报告实际或涉嫌违反法律、《行为准则》、公司政策或我们高道德标准的行为。所有员工、供应商和代表我们开展工作的其他第三方均应遵循这一要求。
价值观
2020 BD launched the first Human Papillomavirus (HPV) test with extended genotyping to detect more types of HPV, the dominant cause of cervical cancer.
2020 BD launched the first sample preparation and flow cytometry system to enable clinical laboratories to fully automate the sample-to-answer process.
2020 BD launched the BD Veritor™ Plus System for rapid detection of COVID-19
2021 BD launched the first atherectomy and thrombectomy device in the U.S. indicated to treat in-stent restenosis.
2021 BD launched the first at-home system in the U.S. indicated for malignant and non-malignant ascites drainage.
2021 BD launched the first ready-to-use aqueous povidone-iodine (PVP-I) surgical irrigation solution.
2021 BD launched the first assay for HPV screening from at-home, self-collected vaginal samples.
2021 BD launched the first smartphone-interpreted rapid at-home COVID-19 test.
2022 BD becomes the first company to combine flow cytometry with fluorescence imaging and image-based decisioning to sort individual cells based on visual details of the cell at exceptionally high speed (15,000 cells per second).
2022 BD celebrates their 125th anniversary by ringing the closing bell at the New York Stock Exchange.
2010 BD Ultra-Fine™ Nano™ Pen Needle is launched.
2014 BD AutoShield Duo™ Safety Pen Needle with Duel Automatic Protective Shields is launched at retail.
2014 BD launched the first FDA-approved drug coated balloon for peripheral artery disease.
2015 BD became the first to integrate IV pumps with electronic health records.
2015 BD acquired CareFusion, a San Diego, California-based medical technology company specializing in two areas: reducing medication errors and prevention of health care-associated infections.
2017 The first clinical lab application of artificial intelligence and robotics to automatically report and release negative urine cultures is utilized.
2017 BD acquired C. R. Bard, a medical device company founded in 1907 in Covington, Georgia.
2019 BD launched the first CHG antiseptic skin preparation product with sterile solution in the U.S.
2019 BD launched the first venous stent to treat iliofemoral venous occlusive disease.
2000 BD launched the BD Nexiva™ Closed IV Catheter System.
2002 BD opened new distribution center in Redlands, California.
2003 BD launched the BD FACSAria™ Cell Sorter.
2004 BD introduced the first power-injectable PICC (Peripherally Inserted Central Catheter).
2007 BD participates in PEPFAR, the U.S. government's global effort to combat HIV and the largest global health program devoted to a single disease.
2007 BD AutoShield™ needle is launched.
2009 BD Vacutainer® RST™ Tube is approved by the FDA.
1990 Sales surpass $2,000,000,000 for the first time.
1991 BD launched the first auto-disable immunization device.
1991 Pen needle is introduced.
1991 BD opens a central distribution center in Temsee, Belgium to ship medical products across Europe, the middle east, and Africa.
1992 BD introduced the BD Vacutainer® Safety-Lok™ Blood Collection Set.
1993 BD launched the first simplified CD4 instrument for HIV.
1995 A joint venture was established in China to produce medical products for China.
1995 BD formed a subsidiary in India to manufacture insulin syringes and to market other medical and diagnostic products to the region.
1997 BD celebrated their 100th anniversary with a refresh to their brand identity.
1999 BD announced a 5-year partnership with UNICEF and the U.S. Fund for UNICEF to help eliminate maternal and neonatal tetanus worldwide.
1999 The world’s shortest, thinnest insulin pen needle is introduced.
1980 BD launched the first automated system for mycobacteria testing.
1981 BD launched the Bactec™ 460TB instrument – the first automated system for TB testing.
1981 A new plant is built in Plymouth, England to manufacture BD Vacutainer® system products and serve a growing European market.
1981 BD sales surpassed $1,000,000,000 for the first time.
1985 BD became the first to harness the highly specific bind properties of monoclonal antibodies.
1986 BD HQ is moved from Rutherford, NJ to Franklin Lakes, NJ.
1986 BD builds a leadership position in peripheral vascular access devices.
1987 BD opened a new manufacturing facility in Singapore.
1987 BD built a plant to manufacture diagnostic products in Fukushima, Japan.
1988 BD launched the first safety engineered syringe.
1989 BD launched the Pyxis MedStation™ 1000 System: the world’s first automated medication dispensing cabinet.
1971 BD launched the Baby Bird® ventilator, the first infant ventilator.
1971 BD launched the first automated blood culture system.
1972 BD launched the first florescence-activated cell sorter.
1973 BD opened a new research center in Research Triangle Park, North Carolina.
1975 BD opened its European HQ in Meylan, France.
1961 BD introduced the Plastipak™ Syringe.
1962 BD launched the first mass production of syringes and needles.
1962 BD became a public company.
1963 BD invited to join the New York Stock Exchange.
1968 BD introduced the first automated blood culture system for TB.
1952 BD launched the first sterile disposable medical device.
1952 BD acquired MAPAD, S.A. de C.V. based in Mexico City, to produce syringes, needles and clinical thermometers for the Mexican market.
1951 The formation of BD Canada, Ltd. marks the beginning of BD international expansion.
1954 Production of the first disposable syringes to be used in the Salk Polio vaccine trial takes place.
1955 BD enters the microbiology field leading to two fundamental innovations: The conversion of sterilized disposables and the emergence of diagnostic medicine.
1955 BD begins using AMI of France to manufacture steel tubes for hypodermic needles. Three years later, BD would acquire AMI and establish BD France S.A.
1956 BD enters the Brazilian syringe market and quickly becomes the largest provider in the country with two modern plants and HQ in Sao Paulo.
1940 BD launched the first sterilization technology for devices.
1942 BD launched the first penicillin injection kit.
1947 BD hired Joseph Kleiner, who brings his multi-fit syringe and his idea for the evacuated tube. (Patented in 1949)
1948 BD founders turn over the company to their sons.
1949 Wesley J. “Jack” Howe joins BD and becomes integral to developing sterility control procedures and refining the process for manufacturing disposable syringes and needles.
1949 BD opens its first manufacturing site outside of New Jersey in Columbus, Nebraska.
1949 BD launched the first Vacutainer® blood collection tube.
1921 Andrew W. “Doc” Fleischer, developer of the mercurial sphygmomanometer, merged his company with BD. Doc Fleischer would go on to develop the modern stethoscope.
1924 BD launched the first insulin injection device.
1925 BD acquired the Yale™ Luer-Lok™ — the first simple, secure method for attaching and removing a needle from a syringe.
1897 BD is founded.
1898 BD acquired its first patent for an all-glass syringe.
1906 BD opened the first syringe and needle factory in the United States.
1913 BD merged with Oscar O.R. Schwidetzky’s surgical import company, bringing his Asepto™ bulb syringe along with helping to develop the American-made ACE® bandage.
Environment,
Social and Governance
2021 Disability Equality Index
Environment,
Social and Governance
2021 Best Place to Work for LGBTQ Equality
Environment,
social and governance
2021 Bloomberg Gender Equality Index
Environment,
Social and Governance
Fortune Change the World 2020
Technology and Innovation
2021 Clarivate Top 100 Global Innovator
Environment,
Social and Governance
2021 DiversityInc Noteworthy Company
The BD Interventional segment focuses on developing innovative surgical, endovascular, urological and critical care interventions that not only meet clinical needs but also deliver value to health systems and improve patients’ lives. Our customers include hospitals and clinics; physicians; ambulatory surgery centers; nurses; and consumers.
BUSINESS UNITS
- Peripheral Intervention
- Surgery
- Urology and Critical Care
The BD Medical segment focuses on providing innovative solutions to reduce the spread of infection, enhance diabetes treatment, advance drug delivery, improve surgical procedures and provide effective and safe medication management. Our customers include hospitals and clinics; physicians; governmental and public health agencies; healthcare workers; retail pharmacies; pharmaceutical and biotech companies; and consumers.
BUSINESS UNITS
- Diabetes Care
- Medication Delivery Solutions
- Medication Management Solutions
- Pharmaceutical Systems
The BD Life Sciences segment delivers innovative solutions from discovery to diagnosis, continually advancing science and clinical outcomes across infectious disease and cancer. Offerings include preanalytical solutions for sample management; immunology research solutions, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics solutions; and differentiated reagents and assays.
BUSINESS UNITS
- Biosciences
- Integrated Diagnostic Solutions